



Essai Clinique

Généré le 07 mai 2024 à partir de

Titre	A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
Protocole ID	CA013-004
ClinicalTrials.gov ID	NCT02754141
Type(s) de cancer	Tumeurs solides
Phase	Phase I-II
Stade	Maladie avancée ou métastatique
Type étude	Traitement
Médicament	BMS-986179 seul vs avec Nivolumab
Institution	CIUSSS DU CENTRE-ouest-DE-L'ILE-DE-MONTREAL  HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
Ville	Montréal
Investigateur principal	Dr Wilson Miller
Coordonnateur	Sally Behjoudi 514-340-8222
Statut	Fermé
But étude	The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
Critères d'éligibilité	• Men and women at least 18 years of age • Advanced solid tumors • Eastern Cooperative Oncology Group (ECOG) 0-1 • Acceptable lab testing results • Allow biopsies
Critères d'exclusion	• Central nervous system (CNS) tumors • Uncontrolled or significant cardiovascular diseases • Active or known autoimmune disease • Organ transplant Other protocol defined inclusion/exclusion criteria could apply